Certara (NASDAQ:CERT) Hits New 52-Week Low – What’s Next?

Certara, Inc. (NASDAQ:CERT)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $5.63 and last traded at $5.6240, with a volume of 4361473 shares changing hands. The stock had previously closed at $5.75.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Leerink Partners reissued an “outperform” rating and set a $10.00 price objective on shares of Certara in a report on Thursday, February 26th. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Barclays reissued an “equal weight” rating and set a $8.00 price target on shares of Certara in a research note on Friday, March 6th. Finally, KeyCorp lowered their price target on shares of Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.10.

Certara Stock Performance

The firm has a fifty day moving average of $7.20 and a 200-day moving average of $9.21. The firm has a market cap of $875.27 million, a P/E ratio of -550.00 and a beta of 1.50. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million for the quarter, compared to the consensus estimate of $103.23 million. During the same period in the prior year, the firm posted $0.15 earnings per share. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently modified their holdings of CERT. AQR Capital Management LLC bought a new position in Certara in the first quarter valued at approximately $259,000. Goldman Sachs Group Inc. raised its position in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after acquiring an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC boosted its position in shares of Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Certara by 29.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after purchasing an additional 21,099 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.